Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CEL SCI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CEL SCI's regulatory disclosures and financial reporting.
CEL-SCI Corporation has called its 2026 annual shareholder meeting for August 14, 2026 in Vienna, Virginia. Shareholders will elect directors, vote on a new 2026 Non-Qualified Stock Option Plan covering up to 2,600,000 shares, and a 2026 Stock Bonus Plan covering up to 400,000 shares.
They will also cast non-binding advisory votes on executive compensation and how often to hold future say-on-pay votes, with the Board recommending every three years, and will vote on ratifying BDO USA, P.C. as independent auditor for the fiscal year ending September 30, 2026. CEL-SCI reports 17,477,144 common shares outstanding as of June 18, 2026 and discloses detailed executive pay, including 2025 CEO total compensation of $919,854.
TALOR EYAL reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP Chief Scientific Officer receives stock grant. Chief Scientific Officer Talor Eyal was granted 2,307 shares of CEL SCI CORP common stock at a reference price of $1.04 per share. After this compensation-related award, Eyal directly holds a total of 9,318 common shares.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant or award of 4,125 shares of common stock on June 30, 2026 at a reported value of $1.04 per share. After this acquisition, she directly owns 17,489 shares of the company’s common stock.
CEL-SCI Corp Chief Executive Officer Geert R. Kersten reported a compensation-related acquisition of 5,192 shares of common stock at $1.04 per share. Following this grant, he directly holds 216,142 common shares and indirectly holds 311,547 common shares as trustee.
CEL-SCI Corporation has priced a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, for expected gross proceeds of $2.5 million before fees and expenses. The offering is expected to close on June 16, 2026, subject to customary conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. The shares are being sold under an effective Form S-3 shelf registration, with ThinkEquity acting as sole placement agent.
CEL-SCI Corporation is offering 2,500,000 shares of common stock at $1.00 per share on a best-efforts basis. The offering is expected to deliver gross proceeds of $2,500,000 and estimated net proceeds of approximately $2.2 million to fund continued development of Multikine and for general corporate purposes. The prospectus supplement notes there is no minimum offering requirement, placement agent fees of $0.07 per share, and that closing is expected on or about June 16, 2026. The company reported 14,977,144 shares outstanding prior to this offering (as of June 12, 2026), and anticipates 17,477,144 shares outstanding after this offering.
CEL SCI CORP director and CEO Geert Kersten reported a significant insider purchase through a related trust. On May 14, 2026, the de Clara Trust, for which Mr. Kersten serves as trustee, bought 300,000 shares of restricted common stock directly from the company at $1.20 per share, equal to the most recent closing price on May 13, 2026.
After this transaction, Mr. Kersten is shown with 210,950 common shares held directly and 311,547 common shares held indirectly as trustee of the de Clara Trust. The filing shows no derivative securities remaining after this activity.
CEL-SCI Corporation reported another loss-making quarter as it advances its lead cancer immunotherapy, Multikine, toward a planned Phase 3 confirmatory registration study. For the six months ended March 31, 2026, the company posted a net loss of about $10.9 million, improving from $13.6 million a year earlier as both research and development and general and administrative expenses declined.
Cash and cash equivalents fell sharply to $1.9 million from $11.0 million at September 30, 2025, while total assets dropped to $17.7 million. Management discloses “substantial doubt” about CEL-SCI’s ability to continue as a going concern and estimates the planned confirmatory Multikine study will cost roughly $30–$35 million, requiring additional financing.
The company highlights Phase 3 data in a defined head and neck cancer target population, where it reports a 5‑year survival rate of 73% with Multikine versus 45% without, and a hazard ratio of 0.35, and is preparing global regulatory filings while relying heavily on future equity or partnership funding to sustain operations.